Regulation of CD8+ T cells and antitumor immunity by Notch signaling

Frontiers in Immunology

Volumn 9, Issue JAN, 2018, Pages

  Tsukumo, Shin Ichi ^a   Yasutomo, Koji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

CD8+ T cells; Granzyme B; Notch; T cells differentiation; Tumor immunity

Indexed keywords

CD19 ANTIGEN; CD3 ANTIBODY; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA SECRETASE INHIBITOR; GRANZYME; INTERLEUKIN 2 RECEPTOR ALPHA; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN JAGGED 1; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR HES 1;

CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHAGAS DISEASE; CYTOTOXICITY; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREGULATION; IMMUNOTHERAPY; INFLUENZA; NONHUMAN; NOTCH SIGNALING; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UPREGULATION;

EID: 85041613837     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00101     Document Type: Review

References (52)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 29:235-71. doi:10.1146/annurev-immunol-031210-101324
2. Tran E, Robbins PF, Rosenberg SA. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol (2017) 18(3):255-62. doi:10.1038/ni.3682
3. Liu R, Luo F, Liu X, Wang L, Yang J, Deng Y, et al. Biological response modifier in cancer immunotherapy. Adv Exp Med Biol (2016) 909:69-138. doi:10.1007/978-94-017-7555-7_2
4. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol (2017). doi:10.1038/nri.2017.131
5. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 12(4):269-81. doi:10.1038/nri3191
6. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 14(8):463-82. doi:10.1038/nrclinonc.2017.43
7. Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol (2017) 47(5):765-79. doi:10.1002/eji.201646875
8. Amsen D, Helbig C, Backer RA. Notch in T cell differentiation: all things considered. Trends Immunol (2015) 36(12):802-14. doi:10.1016/j.it.2015.10.007
9. Tindemans I, Peeters MJW, Hendriks RW. Notch signaling in T helper cell subsets: instructor or unbiased amplifier? Front Immunol (2017) 8:419. doi:10.3389/fimmu.2017.00419
10. Kovall RA, Gebelein B, Sprinzak D, Kopan R. The canonical Notch signaling pathway: structural and biochemical insights into shape, sugar, and force. Dev Cell (2017) 41(3):228-41. doi:10.1016/j.devcel.2017.04.001
11. Tanigaki K, Tsuji M, Yamamoto N, Han H, Tsukada J, Inoue H, et al. Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity (2004) 20(5):611-22. doi:10.1016/S1074-7613(04)00109-8
12. Amsen D, Antov A, Jankovic D, Sher A, Radtke F, Souabni A, et al. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity (2007) 27(1):89-99. doi:10.1016/j.immuni.2007.05.021
13. Auderset F, Schuster S, Coutaz M, Koch U, Desgranges F, Merck E, et al. Redundant Notch1 and Notch2 signaling is necessary for IFNgamma secretion by T helper 1 cells during infection with Leishmania major. PLoS Pathog (2012) 8(3):e1002560. doi:10.1371/journal.ppat.1002560
14. Maekawa Y, Minato Y, Ishifune C, Kurihara T, Kitamura A, Kojima H, et al. Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. Nat Immunol (2008) 9(10):1140-7. doi:10.1038/ni.1649
15. Backer RA, Helbig C, Gentek R, Kent A, Laidlaw BJ, Dominguez CX, et al. A central role for Notch in effector CD8(+) T cell differentiation. Nat Immunol (2014) 15(12):1143-51. doi:10.1038/ni.3027
16. Mathieu M, Duval F, Daudelin JF, Labrecque N. The Notch signaling pathway controls short-lived effector CD8+ T cell differentiation but is dispensable for memory generation. J Immunol (2015) 194(12):5654-62. doi:10.4049/jimmunol.1402837
17. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 12(11):749-61. doi:10.1038/nri3307
18. Sandy AR, Chung J, Toubai T, Shan GT, Tran IT, Friedman A, et al. T cell-specific Notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells. J Immunol (2013) 190(11):5818-28. doi:10.4049/jimmunol.1203452
19. Zhang Y, Sandy AR, Wang J, Radojcic V, Shan GT, Tran IT, et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood (2011) 117(1):299-308. doi:10.1182/blood-2010-03-271940
20. Cho OH, Shin HM, Miele L, Golde TE, Fauq A, Minter LM, et al. Notch regulates cytolytic effector function in CD8+ T cells. J Immunol (2009) 182(6):3380-9. doi:10.4049/jimmunol.0802598
21. Ito T, Allen RM, Carson WF, Schaller M, Cavassani KA, Hogaboam CM, et al. The critical role of Notch ligand Delta-like 1 in the pathogenesis of influenza A virus (H1N1) infection. PLoS Pathog (2011) 7(11):e1002341. doi:10.1371/journal.ppat.1002341
22. Kuijk LM, Verstege MI, Rekers NV, Bruijns SC, Hooijberg E, Roep BO, et al. Notch controls generation and function of human effector CD8+ T cells. Blood (2013) 121(14):2638-46. doi:10.1182/blood-2012-07-442962
23. Mathieu M, Cotta-Grand N, Daudelin JF, Thebault P, Labrecque N. Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. Immunol Cell Biol (2013) 91(1):82-8. doi:10.1038/icb.2012.53
24. Palaga T, Miele L, Golde TE, Osborne BA. TCR-mediated Notch signaling regulates proliferation and IFN-production in peripheral T cells. J Immunol (2003) 171(6):3019-24. doi:10.4049/jimmunol.171.6.3019
25. Sauma D, Ramirez A, Alvarez K, Rosemblatt M, Bono MR. Notch signalling regulates cytokine production by CD8+ and CD4+ T cells. Scand J Immunol (2012) 75(4):389-400. doi:10.1111/j.1365-3083.2012.02673.x
26. Wong KK, Carpenter MJ, Young LL, Walker SJ, McKenzie G, Rust AJ, et al. Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism. J Clin Invest (2003) 112(11):1741-50. doi:10.1172/JCI18020
27. Kijima M, Iwata A, Maekawa Y, Uehara H, Izumi K, Kitamura A, et al. Jagged1 suppresses collagen-induced arthritis by indirectly providing a negative signal in CD8+ T cells. J Immunol (2009) 182(6):3566-72. doi:10.4049/jimmunol.0803765
28. Okamoto M, Takeda K, Joetham A, Ohnishi H, Matsuda H, Swasey CH, et al. Essential role of Notch signaling in effector memory CD8+ T cell-mediated airway hyperresponsiveness and inflammation. J Exp Med (2008) 205(5):1087-97. doi:10.1084/jem.20072200
29. Coutaz M, Hurrell BP, Auderset F, Wang H, Siegert S, Eberl G, et al. Notch regulates Th17 differentiation and controls trafficking of IL-17 and metabolic regulators within Th17 cells in a context-dependent manner. Sci Rep (2016) 6:39117. doi:10.1038/srep39117
30. Fu T, Zhang P, Feng L, Ji G, Wang XH, Zheng MH, et al. Accelerated acute allograft rejection accompanied by enhanced T-cell proliferation and attenuated Treg function in RBP-J deficient mice. Mol Immunol (2011) 48(5):751-9. doi:10.1016/j.molimm.2010.11.016
31. Tindemans I, Lukkes M, de Bruijn MJW, Li BWS, van Nimwegen M, Amsen D, et al. Notch signaling in T cells is essential for allergic airway inflammation, but expression of the Notch ligands Jagged 1 and Jagged 2 on dendritic cells is dispensable. J Allergy Clin Immunol (2017) 140(4):1079-89. doi:10.1016/j.jaci.2016.11.046
32. Bhuyan ZA, Asanoma M, Iwata A, Ishifune C, Maekawa Y, Shimada M, et al. Abrogation of Rbpj attenuates experimental autoimmune uveoretinitis by inhibiting IL-22-producing CD4+ T cells. PLoS One (2014) 9(2):e89266. doi:10.1371/journal.pone.0089266
33. Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, et al. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity (2012) 36(4):623-34. doi:10.1016/j.immuni.2012.01.020
34. Maekawa Y, Ishifune C, Tsukumo S, Hozumi K, Yagita H, Yasutomo K. Notch controls the survival of memory CD4+ T cells by regulating glucose uptake. Nat Med (2015) 21(1):55-61. doi:10.1038/nm.3758
35. Hombrink P, Helbig C, Backer RA, Piet B, Oja AE, Stark R, et al. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. Nat Immunol (2016) 17(12):1467-78. doi:10.1038/ni.3589
36. Sugimoto K, Maekawa Y, Kitamura A, Nishida J, Koyanagi A, Yagita H, et al. Notch2 signaling is required for potent antitumor immunity in vivo. J Immunol (2010) 184(9):4673-8. doi:10.4049/jimmunol.0903661
37. Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol (2016) 17(1):95-103. doi:10.1038/ni.3313
38. Dai K, Huang L, Huang YB, Chen ZB, Yang LH, Jiang YA. 1810011o10 Rik inhibits the antitumor effect of intratumoral CD8+ T cells through suppression of Notch2 pathway in a murine hepatocellular carcinoma model. Front Immunol (2017) 8:320. doi:10.3389/fimmu.2017.00320
39. Sierra RA, Thevenot P, Raber PL, Cui Y, Parsons C, Ochoa AC, et al. Rescue of Notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. Cancer Immunol Res (2014) 2(8):800-11. doi:10.1158/2326-6066.CIR-14-0021
40. Thounaojam MC, Dudimah DF, Pellom ST Jr, Uzhachenko RV, Carbone DP, Dikov MM, et al. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-kappaB crosstalk. Oncotarget (2015) 6(32):32439-55. doi:10.18632/oncotarget.5857
41. Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, et al. Multivalent forms of the Notch ligand DLL-1 enhance antitumor T-cell immunity in lung cancer and improve efficacy of EGFR-targeted therapy. Cancer Res (2015) 75(22):4728-41. doi:10.1158/0008-5472.CAN-14-1154
42. Brzozowa-Zasada M, Piecuch A, Michalski M, Segiet O, Kurek J, Harabin-Slowinska M, et al. Notch and its oncogenic activity in human malignancies. Eur Surg (2017) 49(5):199-209. doi:10.1007/s10353-017-0491-z
43. Baumeister SH, Freeman GJ, DranoffG, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol (2016) 34:539-73. doi:10.1146/annurev-immunol-032414-112049
44. Yu W, Wang Y, Guo P. Notch signaling pathway dampens tumor-infiltrating CD8(+) T cells activity in patients with colorectal carcinoma. Biomed Pharmacother (2017) 97:535-42. doi:10.1016/j.biopha.2017.10.143
45. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 15(7):808-13. doi:10.1038/nm.1982
46. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med (2011) 17(10):1290-7. doi:10.1038/nm.2446
47. Flynn JK, Gorry PR. Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies. Clin Trans Immunol (2014) 3(7):e20. doi:10.1038/cti.2014.16
48. Kondo T, Morita R, Okuzono Y, Nakatsukasa H, Sekiya T, Chikuma S, et al. Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy. Nat Commun (2017) 8:15338. doi:10.1038/ncomms15338
49. de Pooter RF, Zuniga-Pflucker JC. Generation of immunocompetent T cells from embryonic stem cells. Methods Mol Biol (2007) 380:73-81. doi:10.1007/978-1-59745-395-0_5
50. Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res (2007) 67(6):2425-9. doi:10.1158/0008-5472.CAN-06-3977
51. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell (2013) 12(1):31-6. doi:10.1016/j.stem.2012.12.006
52. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 31(10):928-33. doi:10.1038/nbt.2678